Day 1 – Tuesday 10th October
08:50 Welcome Address
Josh Dance, SVP, LSX
09:00 Live Opening Of The Nasdaq Nordic Markets & Nasdaq Welcome
Adam Kostyal, SVP, Head Listings EMEA, Nasdaq .png?width=100&height=100&name=Adam%20Kostyal%2c%20SVP%2c%20Nasdaq%20(moderator).png)
09:10 Back Bay Welcome Address
Jonathan Gertler, CEO, BackBay Life Science Advisors
09:20 Unleashing The Global Potential Of The Nordic Life Science Markets Through Strategic Internationalization
The Nordic region has long been recognized as a global leader in innovation, sustainability, and quality of life, and has also emerged as a hotbed for life science innovation and entrepreneurship with an increasing number of startups. The Nordic region shares a highly interconnected business environment that facilitates cross-border collaboration and knowledge exchange, creating a unique ecosystem that fosters innovation and entrepreneurship, attracting investors and partners from around the world. Despite these advantages, however, the Nordic life science markets face a number of challenges in their efforts to grow and internationalize. This keynote discussion will explore the current state of the Nordic life science markets, including their strengths and weaknesses, and discuss strategies for growing and globalizing the industry in the years ahead.
10:10 How Can Nordic Life Sciences Continue To Be A Global Leader?
AstraZeneca has a bold aspiration to launch 15 new medicines over the coming years and become carbon-neutral. As a Swedish-British company with more than 84.000 employees globally, the company plays a leading role in the Nordics as well as global life sciences. With increased globalization and competition, what is needed if the Nordics should continue to be a leader within life sciences?
Anna-Lena Engwall, Nordic Country President, AstraZeneca
10:30 Morning Break
12:50 Lunch Break
14:45 Beyond The Double Helix: Boldly Advancing The Future Of Cell And Gene Therapies
Successful clinical trials have shown industry stakeholders the value cell and gene therapy offers patients now and as the path of future medicine. Despite the clinical benefits, CGT has not yet achieved significant market penetration. In addition to struggling with production roadblocks, companies also face pricing issues and a global healthcare system unprepared for CGT roll out. With the aim to bring CGT’s to as many patients as possible, this session will explore the latest trends and advancements in cell and gene therapy, and how they are shaping the future of life science industry.
15:40 Afternoon Break
16:10 Building A Strong Ecosystem For Smes: Resources In The Nordics To Help Biotechs Grow
.png?width=100&height=100&name=Farzad%20Abdi-Dezfuli%2c%20Partner%2c%20Sarsia%20Seed%20(1).png)
16:30 Biopharma S&e And Dealmaking In 2023 And Beyond: What’s Next?
New innovations are needed and new ideas fuel growth, but what new innovations and technologies does the world currently need?
This panel gathers top dealmakers at some of the world’s leading big pharma companies, discussing S&E, innovations, and adapting to a constantly shifting environment.
17:30 Drinks Reception
18:30 Networking Party
Day 2 – Wednesday 11th October
09:00 Welcome Address
Adam Griffiths, Senior Conference Director, LSX
09:10 Keynote Panel: Paving The Way For Future Founders: Transitioning From Academic Leadership To Biotech Entrepreneurship
Moving from academia to industry is a significant change for a scientist, but if you are doing it for the right reasons, have a clear path in mind and fully understand the road you are embarking on, it is a decision that can reap huge rewards. Becoming a biotech leader of tomorrow requires a specialized skillset to ensure efficient and stellar development from pre-clinical studies through to market approval.
This panel will discuss how academic founders can set themselves up for success by knowing the key milestones to prepare for, the importance of biotech company culture, and ultimately how to become a strong life science leader.
09:50 The Danish Enterprise Foundation Model: Investing In The Future For Long-term Success
Some of Denmark’s largest pharma companies are all partly owned by independent foundations with dual philanthropic and commercial activities. This model ensures great stability to companies, allowing organizations to be set-up for long-term success and funds channelled into both academia and biotech start-ups. As a rapidly and ever-developing biotech hub, what are the direct and indirect benefits of this model, and what could other countries learn from Denmark?
Moderator: Christian Elling, Managing Partner, Lundbeckfonden BioCapital
11:00 Through The Lens: An International Investor’s Take On The Thriving Nordic Life Science Market
The Nordic region has been experiencing rapid growth in its life science market in recent years, attracting the attention of international investors. As new innovations come to light and competition between companies increases, biotechs who know how to navigate the international investor community will set themselves up for future success. A panel of international biotech investors discuss the Nordic market, and how biotech companies can best position themselves for investment.
12:00 Effective Talent Acquisition And Retention Strategies For Life Sciences In The Nordics
13:00 Lunch Breack
14:00 How Artificial Intelligence Is Shaping The Future Of Drug Discovery, Design, And Development
The pharmaceutical industry is increasingly utilising artificial intelligence (AI) to bring novel treatments to market more rapidly and at a reduced cost. AI and machine learning (ML) have already transformed the way research and drug development are carried out, and these technologies are opening up many new possibilities for innovation in drug development. ML algorithms capable of providing insight and predictions can assist healthcare practitioners, delivering risk factors, diagnoses and treatments for patients earlier on in their care pathway and disease progression.
.jpeg?width=100&height=100&name=Alex%20Zhavoronkov%2c%20CEO%2c%20Insilico%20Medicine%20(1).jpeg)
15:00 Revolutionizing Oncology Drug Discovery: Novel Approaches And Technologies Shaping The Future Of Cancer Treatment
In 2023, Oncology, remains the focus of the majority of life sciences companies, comprising roughly 38% of all products currently with an active research programme, and has grown at 10.5% CAGR over the last five years. With an increased interest in platforms such as cancer vaccines, oncolytic viruses, and targeted protein degradation, what are the latest trends and developments in oncology, and how will this affect future partnering opportunities?
16:00 Close of LSX Nordic Congress 2023
Day 1 - Tuesday 10th October - 11:00
The LSX Nordic Public CEO Forum provides a unique, powerful and valuable space for the candid sharing of ideas and experience between up 15-25 c-suite executives from publicly listed, life sciences companies from the Nordic region. The forum is designed to foster new ideas and create new relationships between attendees so that they can leave with tangible outcomes that will drive their businesses and the sector forward.
The forum is an invitation-only CEO forum where all participants are active discussants. It follows a Chatham House Rule policy and includes presentations, case studies and general discussion focused on brainstorming solutions to the current collective challenges of the group.
The forum features interactive peer review discussions from CEOs and Partners who put forward informative presentations or specific case studies, either success stories or current challenges, and the group asks questions and discusses the challenges around the topic, as well as solutions and ideas.
Some notes:
Hosted by:
Day 1– Tuesday 10th October - 15:45
The LSX Nordic Growth CEO Forum provides a unique, powerful and valuable space for the candid sharing of ideas and experience between 15-25 c-suite executives from privately-held life science companies from the Nordic region. The forum is designed to foster new ideas and create new relationships between attendees so that they can leave with tangible outcomes that will drive their businesses and the sector forward.
The forum is an invitation-only CEO forum where all participants are active discussants. It follows a Chatham House Rule policy and includes presentations, case studies and general discussion focused on brainstorming solutions to the current collective challenges of the group.
The forum features interactive peer review discussions from CEOs and Partners who put forward informative presentations or specific case studies, either success stories or current challenges, and the group asks questions and discusses the challenges around the topic, as well as solutions and ideas.
Some notes:
Co-hosted by:
